Pbi7 Budget Impact Analysis of Introduction of Bevacizumab Biosimilar in the United States From a Payer Perspective

Abstract

This analysis estimated the cost-savings of adding trastuzumab-qyyp for the management of HER2-overexpressing breast and gastric cancer, and gastroesophageal junction (GEJ) adenocarcinoma from French payer and buyer perspectives. Methods: A budget impact model was developed to estimate the cost-savings of trastuzumab-qyyp. Comparators included IV and SC trastuzumab. The French population of 67.19 million was considered for payer perspective and a hypothetical hospital purchasing 10,000 vials of trastuzumab annually was considered for buyer perspective. Costs (drug and administration) and epidemiologic inputs were obtained from public databases. Administration cost was based on the reimbursement provided to hospitals from payer perspective while from buyer perspective it was calculated using healthcare practitioners' wages and time spent. A 76% discount was assumed for trastuzumab-qyyp drug cost relative to IV trastuzumab. Market share was based on a market research study, assuming a 62% conversion of trastuzumab originators to trastuzumab-qyyp. Results: From payer perspective, drug costs decreased by V414,671,781, administration costs increased by V57,030,984 resulting in net cost-savings of V357,640,797 after trastuzumab-qyyp entry. From buyer perspective, drug costs decreased by V101,923,369, administration costs increased by V619,669, resulting in net cost-savings of V101,303,700 after trastuzumab-qyyp entry. Despite the lower administration costs of SC trastuzumab compared to trastuzumab-qyyp, the lower drug costs resulted in net cost-savings. Conclusions: The results demonstrated substantial cost-savings for both payers and buyers after switching patients from trastuzumab originators to trastuzumab-qyyp ® . These costsavings can be used to fund new innovative therapeutics.

Biosimilars in an Era of Rising Oncology Treatment Options

“…Regarding bevacizumab, a study of a hypothetical 10-millionmember health plan estimated that 503 patients would be treated with bevacizumab reference product or biosimilar in year 1 and 676 patients in year 3. Switching from reference product to bevacizumab biosimilar was projected to be associated with a total cost saving of $3,430,967 in year 1 and $14,731,112 in year 3, with more than half associated with patients with colorectal cancer [8]. Based on these types of projections, oncologic biosimilars may help ease the burden of increasing treatment costs, facilitating greater access to important biologic therapies as treatments for cancer.…”

“…The targets can be: proteins that are expressed at high levels in cancer cells, such as HER2 and MET; mutant proteins that drive cancer progression, such as mutant EGFR, MET, HER2 kinase and the cell growth signaling protein BRAF; or fusion genes resulting from chromosomal translocations, involving genes, such as ALK, ROS1, RET and NTRK [15]. Since 2010, new immunotherapy drugs have led to a paradigm shift in cancer therapy by targeting immune cells to trigger the immune system to eradicate tumor cells [1,8]. Major advances were based on immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1) or its ligand (PD-L1); for example, nivolumab and pembrolizumab (anti-PD-1 monoclonal antibodies) and atezolizumab (an anti-PD-L1 monoclonal antibody).…”